Carbapenem-Resistant Klebsiella pneumoniae sepsis in corticosteroid receipt mice: Tigecycline or colistin monotherapy versus tigecycline/colistin combination

Journal of Chemotherapy

Volumn 26, Issue 5, 2014, Pages 276-281

  Demiraslan, Hayati ^a   Dinc, Gokcen ^a   Ahmed, Salman Shaheer ^a   Elmali, Ferhan ^a   Metan, Gokhan ^a   Alp, Emine ^a   Doganay, Mehmet ^a  

^a ERCIYES UNIVERSITY   (Turkey)

Author keywords

Carbapenem resistant K. pneumoniae; Colistin; Experimental sepsis; Methylprednisolone acetate; Tigecycline

Indexed keywords

AMIKACIN; AMPHOTERICIN B LIPID COMPLEX; CD45 ANTIGEN; CEFOTAXIME; CIPROFLOXACIN; COLISTIMETHATE; COLISTIN; COTRIMOXAZOLE; ERTAPENEM; GENTAMICIN; IMIPENEM; KETAMINE; MEROPENEM; METHYLPREDNISOLONE ACETATE; TEICOPLANIN; TIGECYCLINE; VORICONAZOLE; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE; METHYLPREDNISOLONE; MINOCYCLINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COUNT; BACTERIAL GROWTH; BACTERIAL LOAD; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BACTERIUM COLONY; CARBAPENEM RESISTANT KLEBSIELLA PNEUMONIAE SEPSIS; COLONY FORMING UNIT; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG POTENTIATION; EPSILOMETER TEST; EXTRAMEDULLARY HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOLOGY; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; KLEBSIELLA PNEUMONIAE INFECTION; LYMPHOCYTE DEPLETION; MOUSE; NONHUMAN; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE; SEPSIS; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-BACTERIAL AGENTS; CARBAPENEMS; COLISTIN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE, BACTERIAL; KLEBSIELLA PNEUMONIAE; METHYLPREDNISOLONE; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; SEPSIS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84918816526     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/1973947813Y.0000000143     Document Type: Article

References (28)

1. Gaibani P, Ambretti S, Berlingeri A, Gelsomino F, Bielli A, Landini MP, et al. Rapid increase of carbapenemase-producing Klebsiella pneumoniae strains in a large Italian hospital: surveillance period 1 March-30 September 2010. Euro Surveill. 2011;16.
2. Queenan AM, Bush K. Carbapenemases: the versatile betalactamases. Clin Microbiol Rev. 2007;20:440-58.
3. Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis. 2009;9:228-36.
4. Aktas Z, Kayacan CB, Schneider I, Can B, Midilli K, Bauernfeind A. Carbapenem-hydrolyzing oxacillinase, OXA-48, persists in Klebsiella pneumoniae in Istanbul, Turkey. Chemotherapy. 2008;54:101-6.
5. Gulmez D, Woodford N, Palepou MF, Mushtaq S, Metan G, Yakupogullari Y, et al. Carbapenem-resistant Escherichia coli and Klebsiella pneumoniae isolates from Turkey with OXA-48-like carbapenemases and outer membrane protein loss. Int J Antimicrob Agents. 2008;31:523-6.
6. Hirsch EB, Tam VH. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother. 2010;65:1119-25.
7. Nordmann P, Naas T, Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis. 2011;17:1791-8.
8. Albur M, Noel A, Bowker K, MacGowan A. Bactericidal activity of multiple combinations of tigecycline and colistin against NDM-1-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2012;56:3441-3.
9. Akova M, Daikos GL, Tzouvelekis L, Carmeli Y. Interventional strategies and current clinical experience with carbapenemase-producing Gram-negative bacteria. Clin Microbiol Infect. 2012;18:439-48.
10. CLSI CaLSI. Performance standards for antimicrobial susceptibility testing. M100-S21: M100-S21. Wayne, PA: CLSI CaLSI. 2011.
11. CLSI CaLSI. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 9th edn. M07-A9: M07-A9, Wayne, PA: CLSI CaLSI. 2012.
12. EUCAST ECoAST. Breakpoint tables for interpretation of MICs and zone diameters, Version 3.1; 2013.
13. Meletis G, Tzampaz E, Sianou E, Tzavaras I, Sofianou D. Colistin heteroresistance in carbapenemase-producing Klebsiella pneumoniae. J Antimicrob Chemother. 2011;66:946-7.
14. Bergen PJ, Forrest A, Bulitta JB, Tsuji BT, Sidjabat HE, Paterson DL, et al. Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula. Antimicrob Agents Chemother. 2011;55:5134-42.
15. CLSI CaLSI. Methods for determining bacterial activity of antimicrobial agents; approved guideline: M26A. Clinical and Laboratory Standards Institute; 1999.
16. Petersen PJ, Jones CH, Bradford PA. In vitro antibacterial activities of tigecycline and comparative agents by time-kill kinetic studies in fresh Mueller-Hinton broth. Diagn Microbiol Infect Dis. 2007;59:347-9.
17. Pournaras S, Vrioni G, Neou E, Dendrinos J, Dimitroulia E, Poulou A, et al. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay. Int J Antimicrob Agents. 2011;37:244-7.
18. Miller TA, Schaefer FW, 3rd. Characterization of a single dose methylprednisolone acetate immune suppression model using Cryptosporidium muris and Cryptosporidium parvum. Vet Parasitol. 2006;141:66-83.
19. Song JY, Cheong HJ, Lee J, Sung AK, Kim WJ. Efficacy of monotherapy and combined antibiotic therapy for carbapenemresistant Acinetobacter baumannii pneumonia in an immunosuppressed mouse model. Int J Antimicrob Agents. 2009;33:33-9.
20. Montero A, Ariza J, Corbella X, Domenech A, Cabellos C, Ayats J, et al. Efficacy of colistin versus beta-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2002;46:1946-52.
21. Hong T, Moland ES, Abdalhamid B, Hanson ND, Wang J, Sloan C, et al. Escherichia coli: development of carbapenem resistance during therapy. Clin Infect Dis. 2005;40:e84-6.
22. Maherault AC, Nordmann P, Therby A, Pangon B. Efficacy of imipenem for the treatment of bacteremia due to an OXA-48-producing Klebsiella pneumoniae isolate. Clin Infect Dis. 2012;54:577-8.
23. Daly MW, Riddle DJ, Ledeboer NA, Dunne WM, Ritchie DJ. Tigecycline for treatment of pneumonia and empyema caused by carbapenemase-producing Klebsiella pneumoniae. Pharmacotherapy. 2007;27:1052-7.
24. Poudyal A, Howden BP, Bell JM, Gao W, Owen RJ, Turnidge JD, et al. In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae. J Antimicrob Chemother. 2008;62:1311-8.
25. Petersen PJ, Labthavikul P, Jones CH, Bradford PA. In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis. J Antimicrob Chemother. 2006;57:573-6.
26. Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis. 2012;55:943-50.
27. Petrosillo N, Giannella M, Lewis R, Viale P. Treatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art. Expert Rev Anti Infect Ther. 2013;11:159-77.
28. Navarro-San Francisco C, Mora-Rillo M, Romero-Gomez MP, Moreno-Ramos F, Rico-Nieto A, Ruiz-Carrascoso G, et al. Bacteraemia due to OXA-48-carbapenemase-producing Enterobacteriaceae: a major clinical challenge. Clin Microbiol Infect. 2013;19:E72-9.